ArticleInvestigative ophthalmology & visual science2026
Diosgenin Attenuates Photoreceptor Degeneration in an N-Methyl-N-Nitrosourea-Induced Mouse Model of Retinal Degeneration.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Retinitis pigmentosa (RP) is a hereditary retinal disorder distinguished by progressive photoreceptor cell (PRC) loss, in which glial activation can accelerate degeneration. Diosgenin, a natural steroidal sapogenin with potent anti-inflammatory properties, has shown therapeutic potential for ocular and neurodegenerative diseases but has not been explored for retinal degeneration. This study examined the protective role of diosgenin against PRC degeneration and explored potential anti-inflammatory mechanisms in an N-methyl-N-nitrosourea (MNU)-induced mouse model of retinal degeneration. Methods: The model was established by intraperitoneal injection of 50 mg/kg MNU, followed by oral gavage of diosgenin/lutein (positive control)/vehicle. The effects of diosgenin on PRC structure, apoptosis, retinal function, and glial activation were evaluated. Network pharmacology and molecular docking were used to investigate potential mechanisms. Results: Diosgenin preserved retinal integrity and function in MNU-induced mice, with relative preservation of the outer nuclear layer thickness and outer segment (OS) length of rods and cones. Disorganization of OS membrane discs and abnormal morphology of organelles were attenuated, while fundus photographs showed fewer lesions. Furthermore, diosgenin mitigated PRC apoptosis and maintained retinal light responses. Mechanistically, diosgenin ameliorated reactive gliosis of Müller glial cells (MGCs), attenuated the expression levels of inflammatory cytokines and chemokines, and mitigated activation of the IL6ST/JAK2/STAT3 pathway. Conclusions: Diosgenin attenuated PRC degeneration in MNU-induced mice, and one of its mechanisms may involve the attenuation of reactive gliosis in MGCs and inflammatory responses, with possible involvement of the IL6ST/JAK2/STAT3 pathway. Diosgenin may serve as a potential intervention candidate for retinal degenerative diseases, such as RP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.